Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats

Human and Experimental Toxicology

Volumn 31, Issue 7, 2012, Pages 676-685

  Adaramoye, O A ^a   Adesanoye, O A ^a   Adewumi, O M ^a   Akanni, O ^a  

^a UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

kidney; liver; nevirapine; testis; toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; MALONALDEHYDE; NEVIRAPINE; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG TOXICITY; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEMINIFEROUS TUBULE; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; TESTIS TOXICITY;

ANIMALS; ANTI-HIV AGENTS; BILIRUBIN; KIDNEY; LIVER; MALE; MALONDIALDEHYDE; NEVIRAPINE; ORGAN SIZE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SPERM COUNT; SPERM MOTILITY; SPERMATOZOA; TESTIS; TRANSFERASES;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84864146369     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327111424304     Document Type: Article

References (45)

1. Van Sighem AI, Van De Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003 ; 17: 2227-2236
2. Saag MS, Powderly WG, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Top HIV Med. 2002 ; 10: 47-51
3. Harris M, Montaner JSG. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol. 2000 ; 10: 217-229
4. Wit FWNM, Weverling GJ, Weel J, et al. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral therapy. J Infect Dis. 2002 ; 186: 23-31
5. Podzamcer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Expert Opin Pharmacother. 2001 ; 2: 2065-2078
6. Serious adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001 ; 49: 1153-1156
7. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in co-infection. Am J Med. 1999 ; 107: 79S - 84S
8. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis. 2003 ; 3: 173-181
9. Kreisberg R. Clinical problem-solving. We blew it. N Engl J Med. 1995 ; 332: 945-949
10. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity-a challenge for the hepatologist?. J Hepatol. 2002 ; 36: 283-294
11. Mastan SK, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr. 2009 ; 1: 15
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951 ; 193: 265-275
13. Talke H, Schubert GE. Enzymatische Harnstoff bestimmung in Blut and serum in Optischen Test nach Warburg. Klin Wochschr. 1965 ; 174: 43
14. Jaffe M. Ueber den Neiderschlag, welchen Pikrinsäure im normalen harn Erzeught und über eine neue Reaction des Kreatinins. Z Physiol Chem. 1886 ; 10: 391-400
15. Mohun AF, Cook LJ. Simple method for measuring serum level of glutamate-oxaloacetate and glutamate-pyruvate transaminases in laboratories. J Clin Pathol. 1957 ; 10: 394-399
16. Reitman S, Frankel S. A colorimetric method for the determination of serum level of glutamate-oxaloacetate and pyruvate transaminases. Am J Clin Pathol. 1957 ; 28: 56-63
17. Fossati R, Melzid'Eril GV, Turenghi G, et al. A kinetic colorimetric assay of gamma-glutamyltransferase. Clin Chem. 1986 ; 32: 1581-1584
18. King EJ, Armstrong AR Varley H, ed. New Delhi: CBS Publishers ; 1988: 458.
19. Rutkowski RB, Debaare L. An ultra-micro colorimetric method for determination of total and direct serum bilirubin. Clin Chem. 1966 ; 12: 432-438
20. Walls R, Kumar KS, Hochstein P. Aging human erythrocytes. Differential sensitivity of young and old erythrocytes to hemolysis induced by peroxide in the presence of thyroxine. Arch Biochem Biophys. 1976 ; 176: 463-468
21. Moron MA, Depierre JW, Mannervick B. Levels of glutathione, glutathione reductase and glutathione-S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979 ; 582: 67-78
22. McCord JM, Fridovich I. Superoxide dismutase, an enzymatic function for erythrocuperin. J Biol Chem. 1969 ; 244: 6049-6055
23. Aebi H Bergmeyer HV, ed. New York: Verlag Chemie ; 1974: 673-684.
24. Zemjanis R Diagnostic and therapeutic technique in animal reproduction: collection and evaluation of semen. Baltimore, MD: William and Wilkins Company ; 1970: 139-153.
25. Rezvanfar M, Sadrkhanlou R, Ahmadi A, et al. Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress. Hum Exp Toxicol. 2008 ; 27: 901-910
26. Pant N, Srivastava SP. Testicular and spermatotoxic effects of quinalphos in rats. J Appl Toxicol. 2003 ; 23: 271-274
27. Wells ME, Awa OA. New technique for assessing acrosomal characteristics of spermatozoa. J Dairy Sci. 1970 ; 227: 53
28. Walli RK, Michl GM, Bogner JR, et al. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res. 2001 ; 6: 413-421
29. Dieterich D, Stern J, Robinson P, et al. Analyses of 4 key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B and C seropositivity and baseline liver function tests. ; 2001 ; 2001..
30. Bruck S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res. 2008 ; 13: 343-348
31. Sulkowski MS, Thomas DL, Metha SH, et al. Hepatotoxicity associated with efavitenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002 ; 35: 182-189
32. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected patient. Clin Liver Dis. 2003 ; 7: 179-194
33. Beltran B, Quintero M, Garcia-Zaragoza E, et al. Inhibition of mitochondrial respiration by endogenous nitric oxide: a critical step in Fas signalling. Proc Natl Acad Sci U S A. 2002 ; 99: 8892-8897
34. Rej R. Aspartate aminotransferase activity and isoenzymes proportions in human liver tissue. Clin Chem. 1997 ; 24: 1971-1978
35. Goldberg DM, Watts C. Serum enzyme changes as evidence of liver reaction to oral alcohol. Gastroenterology. 1965 ; 49: 256-261
36. Sillanaukee P. Laboratory markers of alcohol abuse. Alcohol. 1996 ; 31: 613-616
37. Hulgan T, Morrow J, D'Aquila RT, et al. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis. 2003 ; 37: 1711-1717
38. Morrow JD, Roberts LJ. The isoprostanes: unique bio-active products of lipid peroxidation. Prog Lipid Res. 1997 ; 36: 1-21
39. Redhage LA, Shintani A, Haas DW, et al. Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. HIV Clin Trials. 2009 ; 10: 181-192
40. Stehbens WE. Oxidative stress in viral hepatitis and AIDS. Exp Mol Pathol. 2004 ; 77: 121-132
41. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005 ; 45: 51-88
42. Cathcart RF. Vitamin C: the nontoxic, nonrate-limited, antioxidant free radical scavenger. Med Hypo. 1985 ; 18: 61-77
43. Vernet P, Aitken RJ, Drevet JR. Antioxidant strategies in the epidydimis. Mol Cell Endocrinol. 2004 ; 216: 31-39
44. El Daly E. Effect of methimazole and fish oil treatment on gentamicin hephrotoxicity in rats. J Islamic Acad Sci. 1996 ; 9: 37-48
45. Jaramillo-Juarez F, Rodriquez-Vazquez ML, Rincon-Sanchez AR, et al. Acute renal failure induced by carbon tetrachloride in rats with hepatic cirrhosis. Ann Hepatol. 2008 ; 7: 331-338